{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:42:57Z","timestamp":1778899377606,"version":"3.51.4"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T00:00:00Z","timestamp":1587513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science and Technology Department","award":["2016ZX09101120-006"],"award-info":[{"award-number":["2016ZX09101120-006"]}]},{"name":"National Science and Technology Department","award":["2017ZX10304402"],"award-info":[{"award-number":["2017ZX10304402"]}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2016-I2M-2-006"],"award-info":[{"award-number":["2016-I2M-2-006"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Prophylactic vaccines are critical in preventing hand, foot, and mouth disease (HFMD) primarily caused by human enterovirus 71 (EV71) infection. Children aged less than 5\u2009years are especially susceptible to EV71 infections. In addition to the development of vaccines containing the inactivated virus, those containing virus-like particles (VLPs) with repeated antigens also constitute an effective preventive strategy for EV71 infections, with safety and productivity advantages. We previously developed a fusion protein composed with truncated peptides of the EV71 capsid protein, which assembled into spherical particles. This study aimed to assess the immunoprotective effects of this fusion protein as a vaccine candidate in a mouse model of EV71 infection.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To evaluate the protective effect of fusion protein vaccine candidate, neonatal mice born by immunized female mice, as well as normal neonatal mice immunized twice were infected with EV71 virus. Whereafter, the survival rates, clinical scores and viral loads were measured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The high dosage and booster immunization helped induce specific serum antibodies with high neutralization titers, which were transferred to neonatal mice, thereby facilitating effective resistance towards EV71 infection. An active immune response was also observed in neonatal mice which generated following immunization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present results suggest that this fusion protein is a suitable vaccine candidate in treating EV71 infections.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-020-01328-8","type":"journal-article","created":{"date-parts":[[2020,4,22]],"date-time":"2020-04-22T17:02:39Z","timestamp":1587574959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections"],"prefix":"10.1186","volume":"17","author":[{"given":"Jiangning","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Binbin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongdong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,22]]},"reference":[{"key":"1328_CR1","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1093\/infdis\/129.3.304","volume":"129","author":"NJ Schmidt","year":"1974","unstructured":"Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis. 1974;129:304\u20139.","journal-title":"J Infect Dis"},{"key":"1328_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/jmv.21374","volume":"81","author":"B Ortner","year":"2009","unstructured":"Ortner B, Huang CW, Schmid D, Mutz I, et al. Epidemiology of enterovirus types causing neurological disease in Austria 1999-2007: detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J Med Virol. 2009;81:317\u201324.","journal-title":"J Med Virol"},{"key":"1328_CR3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1086\/592988","volume":"198","author":"AL Fowlkes","year":"2008","unstructured":"Fowlkes AL, Honarmand S, Glaser C, Yagi S, et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis. 2008;198:1685\u201391.","journal-title":"J Infect Dis"},{"key":"1328_CR4","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00705-009-0413-x","volume":"154","author":"S Diedrich","year":"2009","unstructured":"Diedrich S, Weinbrecht A, Schreier E. Seroprevalence and molecular epidemiology of enterovirus 71 in Germany. Arch Virol. 2009;154:1139\u201342.","journal-title":"Arch Virol"},{"key":"1328_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14787210.2014.895666","volume":"12","author":"SM Wang","year":"2014","unstructured":"Wang SM, Liu CC. Update of enterovirus 71 infection: epidemiology, pathogenesis and vaccine. Expert Rev Anti-Infect Ther. 2014;12:447\u201356.","journal-title":"Expert Rev Anti-Infect Ther"},{"key":"1328_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1086\/314032","volume":"31","author":"LG Chan","year":"2000","unstructured":"Chan LG, Parashar UD, Lye MS, et al. Deaths of children during an outbreak of hand, foot, and mouth disease in Sarawak, Malaysia: clinical and pathological characteristics of the disease. For the outbreak study group. Clin Infect Dis. 2000;31:678\u201383.","journal-title":"Clin Infect Dis"},{"key":"1328_CR7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1056\/NEJM199909233411301","volume":"341","author":"M Ho","year":"1999","unstructured":"Ho M, Chen ER, Hsu KH, et al. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus epidemic working group. N Engl J Med. 1999;341:929\u201335.","journal-title":"N Engl J Med"},{"key":"1328_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0887-8994(98)00087-3","volume":"20","author":"H Komatsu","year":"1999","unstructured":"Komatsu H, Shimizu Y, Takeuchi Y, et al. Outbreak of severe neurologic involvement associated with Enterovirus 71 infection. Pediatr Neurol. 1999;20:17\u201323.","journal-title":"Pediatr Neurol"},{"key":"1328_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S0022-3476(98)70155-6","volume":"133","author":"LC Lum","year":"1998","unstructured":"Lum LC, Wong KT, Lam SK, et al. Fatal enterovirus 71 encephalomyelitis. J Pediatr. 1998;133:795\u20138.","journal-title":"J Pediatr"},{"key":"1328_CR10","doi-asserted-by":"crossref","unstructured":"Chang PC, Chen SC, Chen KT. The current status of the disease caused by Enterovirus 71 infections: epidemiology, pathogenesis, molecular epidemiology, and vaccine development. Int J Environ Res Public Health. 2016;13:890.","DOI":"10.3390\/ijerph13090890"},{"key":"1328_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.7774\/cevr.2017.6.1.4","volume":"6","author":"EJ Yi","year":"2017","unstructured":"Yi EJ, Shin YJ, Kim JH, et al. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res. 2017;6:4\u201314.","journal-title":"Clin Exp Vaccine Res"},{"key":"1328_CR12","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1080\/21645515.2018.1442997","volume":"14","author":"Y Hu","year":"2018","unstructured":"Hu Y, Zeng G, Chu K, et al. Five-year immunity persistence following immunization with inactivated enterovirus 71 type (EV71) vaccine in healthy children: a further observation. Hum Vaccin Immunother. 2018;14:1517\u201323.","journal-title":"Hum Vaccin Immunother."},{"key":"1328_CR13","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(13)70342-6","volume":"14","author":"W Xing","year":"2014","unstructured":"Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008-12: an epidemiological study. Lancet Infect Dis. 2014;14:308\u201318.","journal-title":"Lancet Infect Dis"},{"key":"1328_CR14","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1304923","volume":"370","author":"F Zhu","year":"2014","unstructured":"Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med. 2014;370:818\u201328.","journal-title":"N Engl J Med"},{"key":"1328_CR15","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1303224","volume":"370","author":"R Li","year":"2014","unstructured":"Li R, Liu L, Mo Z, Wang X, et al. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med. 2014;370:829\u201337.","journal-title":"N Engl J Med"},{"key":"1328_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1586\/14760584.2016.1138862","volume":"15","author":"QY Mao","year":"2016","unstructured":"Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD). Expert Rev Vaccines. 2016;15:599\u2013606.","journal-title":"Expert Rev Vaccines."},{"key":"1328_CR17","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.4161\/hv.28397","volume":"10","author":"YJ Chen","year":"2014","unstructured":"Chen YJ, Meng FY, Mao Q, et al. Clinical evaluation for batch consistency of an inactivated enterovirus 71 vaccine in a large-scale phase 3 clinical trial. Hum Vaccin Immunother. 2014;10:1366\u201372.","journal-title":"Hum Vaccin Immunother."},{"key":"1328_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.bej.2016.10.009","volume":"117","author":"L Xue","year":"2017","unstructured":"Xue L, Liu JN, Wang Q, et al. Purification and assembling a fused capsid protein as an enterovirus 71 vaccine candidate from inclusion bodies to pentamer-based nanoparticles. Biochem Eng J. 2017;117:139\u201346.","journal-title":"Biochem Eng J"},{"key":"1328_CR19","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1016\/j.vaccine.2016.02.077","volume":"34","author":"Z Reed","year":"2016","unstructured":"Reed Z, Cardosa MJ. Status of research and development of vaccines for enterovirus 71. Vaccine. 2016;34:2967\u201370.","journal-title":"Vaccine."},{"key":"1328_CR20","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/j.vaccine.2011.12.081","volume":"30","author":"YL Lin","year":"2012","unstructured":"Lin YL, Yu CI, Hu YC, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine. 2012;30:1305\u201312.","journal-title":"Vaccine."},{"key":"1328_CR21","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/bit.25159","volume":"111","author":"LH Lua","year":"2014","unstructured":"Lua LH, Connors NK, Sainsbury F, et al. Bioengineering virus-like particles as vaccines. Biotechnol Bioeng. 2014;111:425\u201340.","journal-title":"Biotechnol Bioeng"},{"key":"1328_CR22","first-page":"e01330","volume":"92","author":"X Wang","year":"2018","unstructured":"Wang X, Ku Z, Zhang X, et al. Structure, immunogenicity, and protective mechanism of an engineered Enterovirus 71-like particle vaccine mimicking 80S empty capsid. J Virol. 2018;92:e01330\u201317.","journal-title":"J Virol"},{"key":"1328_CR23","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.vaccine.2012.10.083","volume":"31","author":"N Kushnir","year":"2012","unstructured":"Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31:58\u201383.","journal-title":"Vaccine."},{"key":"1328_CR24","first-page":"94","volume":"7","author":"W Zhang","year":"2018","unstructured":"Zhang W, Dai W, Zhang C, et al. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect. 2018;7:94.","journal-title":"Emerg Microbes Infect"},{"key":"1328_CR25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057601","volume":"8","author":"Z Ku","year":"2013","unstructured":"Ku Z, Ye X, Huang X, et al. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps. PLoS One. 2013;8:e57601.","journal-title":"PLoS One"},{"key":"1328_CR26","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1080\/21645515.2015.1053675","volume":"11","author":"S Sun","year":"2015","unstructured":"Sun S, Gao F, Mao Q, et al. Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice. Hum Vaccin Immunother. 2015;11:2406\u201313.","journal-title":"Hum Vaccin Immunother"},{"key":"1328_CR27","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.vaccine.2008.01.058","volume":"26","author":"YC Chung","year":"2008","unstructured":"Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine. 2008;26:1855\u201362.","journal-title":"Vaccine."},{"key":"1328_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1743-422X-7-47","volume":"7","author":"CS Jia","year":"2010","unstructured":"Jia CS, Liu JN, Li WB, et al. The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments. Virol J. 2010;7:47.","journal-title":"Virol J"},{"key":"1328_CR29","doi-asserted-by":"publisher","first-page":"7444","DOI":"10.1016\/j.vaccine.2010.08.080","volume":"28","author":"JN Liu","year":"2010","unstructured":"Liu JN, Wang W, Duo JY, et al. Combined peptides of human enterovirus 71 protect against virus infection in mice. Vaccine. 2010;28:7444\u201351.","journal-title":"Vaccine."},{"key":"1328_CR30","doi-asserted-by":"publisher","first-page":"7591","DOI":"10.1128\/JVI.00768-08","volume":"82","author":"H Wang","year":"2008","unstructured":"Wang H, Sun J, Goldstein H. Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol. 2008;82:7591\u2013600.","journal-title":"J Virol"},{"key":"1328_CR31","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1212\/01.wnl.0000262031.18018.1a","volume":"68","author":"GL Bowman","year":"2007","unstructured":"Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68:1809\u201314.","journal-title":"Neurology."},{"key":"1328_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/1743-422X-8-483","volume":"8","author":"J Liu","year":"2011","unstructured":"Liu J, Yang Y, Xu Y, et al. Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virol J. 2011;8:483.","journal-title":"Virol J"},{"key":"1328_CR33","first-page":"493","volume":"27","author":"LJMMH Reed","year":"1938","unstructured":"Reed LJMMH. A simple method of estimating fifty percent endpoints. Am J Hyg. 1938;27:493\u20137.","journal-title":"Am J Hyg"},{"key":"1328_CR34","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1086\/527326","volume":"197","author":"ZH Li","year":"2008","unstructured":"Li ZH, Li CM, Ling P, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis. 2008;197:854\u20137.","journal-title":"J Infect Dis"},{"key":"1328_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1093\/infdis\/jiw502","volume":"215","author":"M Wei","year":"2017","unstructured":"Wei M, Meng F, Wang S, et al. 2-year efficacy, immunogenicity, and safety of Vigoo Enterovirus 71 vaccine in healthy Chinese children: a randomized open-label study. J Infect Dis. 2017;215:56\u201363.","journal-title":"J Infect Dis"},{"key":"1328_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1479-0556-5-6","volume":"5","author":"WS Tung","year":"2007","unstructured":"Tung WS, Bakar SA, Sekawi Z, et al. DNA vaccine constructs against enterovirus 71 elicit immune response in mice. Genet Vaccines Ther. 2007;5:6.","journal-title":"Genet Vaccines Ther"},{"key":"1328_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.bbrc.2012.11.035","volume":"430","author":"M Wang","year":"2013","unstructured":"Wang M, Jiang S, Wang Y. Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice. Biochem Biophys Res Commun. 2013;430:387\u201393.","journal-title":"Biochem Biophys Res Commun"},{"key":"1328_CR38","doi-asserted-by":"publisher","first-page":"7322","DOI":"10.1016\/j.vaccine.2017.10.101","volume":"35","author":"C Huo","year":"2017","unstructured":"Huo C, Yang J, Lei L, et al. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. Vaccine. 2017;35:7322\u201330.","journal-title":"Vaccine."},{"key":"1328_CR39","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1128\/JVI.00289-14","volume":"88","author":"T Meng","year":"2014","unstructured":"Meng T, Kwang J. Attenuation of human enterovirus 71 high-replication-fidelity variants in AG129 mice. J Virol. 2014;88:5803\u201315.","journal-title":"J Virol"},{"key":"1328_CR40","doi-asserted-by":"publisher","first-page":"9386","DOI":"10.1128\/JVI.02856-06","volume":"81","author":"M Arita","year":"2007","unstructured":"Arita M, Nagata N, Iwata N, et al. An attenuated strain of enterovirus 71 belonging to genotype a showed a broad spectrum of antigenicity with attenuated neurovirulence in cynomolgus monkeys. J Virol. 2007;81:9386\u201395.","journal-title":"J Virol"},{"key":"1328_CR41","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/14760584.2018.1430572","volume":"17","author":"W Gu","year":"2018","unstructured":"Gu W, Zeng G, Hu YM, et al. A comparative analysis of immunogenicity and safety of an enterovirus 71 vaccine between children aged 3-5 years and infants aged 6-35 months. Expert Rev Vaccines. 2018;17:257\u201362.","journal-title":"Expert Rev Vaccines"},{"key":"1328_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181182","volume":"12","author":"D Zhao","year":"2017","unstructured":"Zhao D, Sun B, Sun S, et al. Characterization of human enterovirus71 virus-like particles used for vaccine antigens. PLoS One. 2017;12:e0181182.","journal-title":"PLoS One"},{"key":"1328_CR43","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.3390\/v7041558","volume":"7","author":"P Fan","year":"2015","unstructured":"Fan P, Li X, Sun S, et al. Identification of a common epitope between enterovirus 71 and human MED25 proteins which may explain virus-associated neurological disease. Viruses. 2015;7:1558\u201377.","journal-title":"Viruses."}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01328-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-020-01328-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-020-01328-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T23:55:30Z","timestamp":1619049330000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-020-01328-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,22]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1328"],"URL":"https:\/\/doi.org\/10.1186\/s12985-020-01328-8","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,22]]},"assertion":[{"value":"24 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The mice experiments were approved by the Animal Care and Use Committee of the Institute of Laboratory Animal Science of Chinese Academy of Medical Sciences (ILAS-PG-2015-014). Not applicable for consent to participate.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that there are no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}